In a LinkedIn post, the Fédération Française des Diabetiques said it “welcomes the inclusion of Omnipod 5” on its list of reimbursable products and services.
Omnipod 5, an insulin patch pump, delivers automated management for type 1 diabetes. France’s Haute Autorité de Santé — the country’s high health authority — issued an indication for the system to target adults and children over two years of age, living with type 1 diabetes whose glycemic control is insufficient despite intensive treatment for more than six months.
In France, the prescription of Omnipod 5, except in particular medical situations, comes for only those whose consumption is less than or equal to 60 units of insulin per day. It remains unsuitable for children requiring a base flow rate of less than 0.05 units/hour, the federation said.
According to the Fédération Française des Diabetiques, authorities officially published the reimbursement decision today, May 7, 2024. It officially goes into effect in 13 days, on May 20, the LinkedIn post said.
French reimbursement marks the latest good news for Insulet overseas. Last month, the company expressed excitement as a new diabetes initiative in the UK began rolling out its insulin delivery technology.
More about the Insulet Omnipod 5
The latest-generation Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January 2022. Insulet commenced its U.S. full-market launch in August 2022. The Omnipod 5 picked up CE mark approval for ages two and up in September 2022.
Omnipod 5, a tubeless pod, features SmartAdjust technology. It integrates with the Dexcom 6 continuous glucose monitor (CGM). With CGM data, SmartAdjust predicts where glucose will be 60 minutes into the future every five minutes. Omnipod 5 then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.
The device also features the Omnipod 5 mobile app with an integrated SmartBolus calculator, too. Users can download the app onto a compatible smartphone or use the Omnipod 5 controller.
It’s the only tubeless, hybrid closed-loop system approved in Europe with integration with two CGM sensor brands in Abbott and Dexcom.
